Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane/tazobactam

BMJ Case Reports

Volumn 2017, Issue , 2017, Pages

  Kurtzhalts, Kari E ^a   Mergenhagen, Kari A ^a   Manohar, Akshay ^a,b   Berenson, Charles S ^a,b  

^a VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; C REACTIVE PROTEIN; CEFDINIR; CEFEPIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ADULT; ARTICLE; BLADDER FISTULA; BLADDER NECK STENOSIS; BLOOD CLOTTING; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOTOMY; DEBRIDEMENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; EXTERNAL BEAM RADIOTHERAPY; GROUP B STREPTOCOCCAL INFECTION; HEMATURIA; HUMAN; INTERSTITIAL NEPHRITIS; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PROSTATE CANCER; PROSTATECTOMY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PUBIS SYMPHYSIS; PYURIA; RECURRENT INFECTION; SMALL INTESTINE OBSTRUCTION; STREPTOCOCCUS AGALACTIAE; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; URINE INCONTINENCE; URINE RETENTION; ANALOGS AND DERIVATIVES; COMPLICATION; FISTULA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

CEPHALOSPORINS; CYSTECTOMY; DEBRIDEMENT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FISTULA; HUMANS; MALE; MIDDLE AGED; OSTEOMYELITIS; PENICILLANIC ACID; PSEUDOMONAS INFECTIONS; PUBIC SYMPHYSIS; TREATMENT OUTCOME;

EID: 85016570969     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-217005     Document Type: Article

References (16)

1. Gupta S, Zura RD, Hendershot EF, et al. Pubic symphysis osteomyelitis in the prostate cancer survivor: Clinical presentation, evaluation, and management. Urology 2015;85:684-90.
2. Robison CM, Gor RA, Metro MJ. Pubic bone osteomyelitis after salvage high-intensity focused ultrasound for prostate cancer. Curr Urol 2013;7:149-51.
3. Moore DC, Keegan KA, Resnick MJ, et al. A 57-year-old man with a history of prostatectomy and pelvic irradiation presents with recurrent urinary tract infections, hematuria, and pelvic pain. Urology 2013;81:221-5.
4. Matsushita K, Ginsburg L, Mian BM, et al. Pubovesical fistula: A rare complication after treatment of prostate cancer. Urology 2010;80:446-51.
5. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1. 2016. J Natl Compr Canc Netw 2016;14:19-30.
6. Frieden T. Antibiotic resistant threats in the United States, 2013. Atlanta: Centers for Disease Control and Department of Health and Human Services, 2013.
7. Ortwine JK, Kaye KS, Li J, et al. Colistin: Understanding and applying recent pharmacokinetic advances. Pharmacotherapy 2015;35:11-16.
8. Landersdorfer CB, Bulitta JB, Kinzig M, et al. Penetration of antibacterials into bone: Pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009;48:89-124.
9. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: A novel antipseudomonal cephalosporin and beta-lactamase-inhibitor combination. Infect Drug Resist 2013;6:215-23.
10. Bremmer DN, Nicolau DP, Burcham P, et al. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy 2016;36:e30-3.
11. Jolliff JC, Ho J, Joson J, et al. Treatment of polymicrobial osteomyelitis with ceftolozane-tazobactam: Case report and sensitivity testing of isolates. Case Rep Infect Dis 2016;2016:1628932. Epub 2016 Jun 29; doi:10. 1155/2016/1628932.
12. Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 2012;56:3086-91.
13. Merck Sharp & Dohme Corp. Zerbaxa Package Insert. July 2015 (updated Oct 2016).
14. Robinson JL, Hameed T, Carr S. Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic. Clin Infect Dis 2002;35:26-31.
15. Kleinknecht D, Kanfer A, Morel-Maroger L, et al. Immunologically mediated drug-induced acute renal failure. Contrib Nephrol 1978;10:42-52.
16. Blumenthal KG, Youngster I, Shenoy ES, et al. Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting. Antimicrob Agents Chemother 2014;58:3137-43.